| Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials M Eugenia-Toledo-Romaní, L Verdecia-Sánchez, M Rodríguez-González, ... Vaccine 40 (31), 4220-4230, 2022 | 38 | 2022 |
| A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles D Santana-Mederos, R Perez-Nicado, Y Climent, L Rodriguez, ... RSC chemical biology 3 (2), 242-249, 2022 | 18 | 2022 |
| In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 … LA Espinosa, Y Ramos, I Andújar, EO Torres, G Cabrera, A Martín, ... Analytical and Bioanalytical Chemistry 413 (30), 7559-7585, 2021 | 13 | 2021 |
| Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme. ME Toledo-Romani, LV Sanchez, MR Gonzalez, LR Noda, CV Silva, ... | 11 | 2021 |
| In-solution buffer-free digestion for the analysis of SARS-CoV-2 RBD proteins allows a full sequence coverage and detection of post-translational modifications in a single ESI … LA Espinosa, Y Ramos, I Andújar, EO Torres, G Cabrera, A Martín, ... BioRxiv, 2021.05. 10.443404, 2021 | 8 | 2021 |
| Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens T Boggiano-Ayo, J Palacios-Oliva, S Lozada-Chang, ... Frontiers in Bioengineering and Biotechnology 11, 1287551, 2023 | 1 | 2023 |
| Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein B Pérez-Massón, Y Quintana-Pérez, Y Tundidor, D Pérez-Martínez, ... Scientific Reports 14 (1), 712, 2024 | | 2024 |
| Establecimiento del esquema de purificación de los antígenos de SOBERANA® 02, SOBERANA® Plus y SOBERANA 01 DM Oca-García, SL Lozada-Chang, T Boggiano-Ayo, ... Vaccimonitor 33, 2024 | | 2024 |
| Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles G Rojas, E Relova-Hernández, A Pérez-Riverón, C Castro-Martínez, ... Communications Biology 6, 2023 | | 2023 |
| Safety and Immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.(preprint) ME Toledo-Romani, LV Sanchez, MR Gonzalez, LR Noda, CV Silva, ... | | 2021 |
Gertrudis RojasSenior researcher and Head of the Protein Engineering Department, Center of Molecular ImmunologyVerified email at cim.sld.cu
